Key Takeaways
- HIMS tumbles in extended trading as Q1 profitability concerns outweigh revenue gains.
- Rising subscriber base provides support, but earnings pressure sends shares downward.
- Forward guidance signals expansion, though margin deterioration maintains downward pressure.
- Extended-hours decline follows Q1 earnings reversal from prior-year profitability.
- GLP-1 product expansion offers growth potential amid profit headwinds dragging stock lower.
Shares of Hims & Hers Health (HIMS) experienced significant after-hours declines despite posting quarterly revenue increases. The stock finished regular trading at $29.14, gaining 3.08%, before plummeting 9.75% to $26.30 following the earnings announcement. Investors reacted negatively to deteriorating profitability measures, compressed margins, and a dramatic year-over-year shift from profit to loss.
Hims & Hers Health, Inc., HIMS
Top-Line Expansion Overshadowed by Bottom-Line Deterioration
Hims & Hers delivered first-quarter revenue totaling $608.1 million, representing a 4% improvement over the $586.0 million generated in the comparable period last year. The uptick demonstrated sustained consumer interest in its telehealth offerings. Nevertheless, the incremental revenue advance proved insufficient to alleviate investor anxiety surrounding profitability erosion.
Gross margin contracted sharply to 65% from 73% recorded in the year-ago quarter. This compression reflected elevated operational expenses tied to the company’s broadening healthcare delivery model. The margin deterioration undermined earnings quality despite the expanded revenue footprint.
The company recorded a net loss of $92.1 million during the quarter. This contrasted sharply with net income of $49.5 million achieved in the same quarter last year. Adjusted EBITDA similarly declined to $44.3 million from $91.1 million.
User Base Expands While Domestic Revenue Contracts
Hims & Hers concluded the quarter serving nearly 2.6 million subscribers. This represented a 9% year-over-year expansion from 2.37 million subscribers previously. The growing customer base provided the platform with enhanced scale for delivering tailored healthcare solutions.
Average monthly revenue per subscriber decreased to $80 from $85. The 6% reduction highlighted challenges in maximizing customer value. This monetization weakness partially negated the benefits derived from subscriber expansion.
Domestic revenue contracted 8% to $529.9 million. Conversely, international revenue surged to $78.2 million from just $7.3 million previously. This substantial overseas growth helped cushion the impact of weakening domestic performance.
Forward Projections Emphasize Growth While Cost Pressures Persist
Hims & Hers anticipates second-quarter revenue ranging from $680 million to $700 million. The company also projects adjusted EBITDA between $35 million and $55 million. This guidance implies an EBITDA margin of approximately 5% to 8%.
For the complete fiscal year 2026, management forecasts revenue spanning $2.8 billion to $3.0 billion. Adjusted EBITDA is expected to reach between $275 million and $350 million. These projections explicitly exclude any potential impact from the pending Eucalyptus acquisition.
The company is actively broadening its portfolio of branded GLP-1 medications and entering additional care verticals. Management also announced plans to transition from quarterly to annual shareholder communications. Despite these strategic initiatives, the after-hours selloff demonstrated that HIMS stock remains vulnerable to margin compression and earnings inconsistency.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
